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Personalized medicine epitomizes an evolving model of care tailored to the 
individual patient. This emerging paradigm harnesses radical technological 
advances to define molecular characteristics of each patient and decipher their 
unique pathophysiological processes. Translated into individualized algorithms, 
the practice of personalized medicine aims to predict, prevent and cure disease 
without afflicting therapeutic adverse events. While the transformative power of 
personalized medicine is generally recognized by physicians, patients and 
payers, the complexity of translating discoveries into new modalities that 
transform healthcare is less appreciated. We often consider the flow of 
innovation and technology along a continuum of discovery, development, 
regulation, and application bridging the bench with the bedside. However, this 
process also can be viewed through a complementary prism, as a necessary 
supply chain of services and providers, each making essential contributions to 
the development of the final product to maximize value to consumers. 
Considering personalized medicine in this context of supply chain management 
highlights essential points of vulnerability and/or scalability that can ultimately 
constrain or potentiate translation of the biological revolution into individualized 
diagnostics and therapeutics for optimized value creation and delivery. 
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The whole is greater than the sum of the parts ― Aristotle 
It is generally appreciated that the revolution in biology is transforming healthcare 
from one-size-fits-all therapeutics, to individual tailored disease management.1,2 
Science and medicine are increasingly providing molecular solutions that offer 
unprecedented opportunities to intervene in disease risk, prevention, prognosis and 
cure.3 Emerging technology platforms provide diagnostics that identify corruption of 
individual molecular circuits disrupting signaling networks and organismal ecosystems 
which can be repaired through genomic, molecular or regenerative interventions 
specifically tailored to individual pathophysiology.4 This scientific revolution drives the 
development of personalized medicine, which exploits insights in molecular pathology to 
generate tailored mechanism-based therapeutics and enhance their curative 
effectiveness, while minimizing adverse events.5 The expanding toolbox of gene-based, 
molecular, omic, and regenerative technologies offers unparalleled opportunities to 
personalize diagnostics and therapeutics that can be applied across diseases, 
ethnicities, and geographies.6, 7  
The fruits of this revolution in creating personalized diagnostic and therapeutic 
products are generally recognized by patients and their healthcare providers.7, 8 What 
may be less appreciated is the complexity of processes leading from laboratory-based 
discovery to individualized patient management algorithms in practice. We typically 
consider the science of translational therapeutics in discreet sequential steps in which 
the flow of information and technology moves from left to right along a continuum, from 
fundamental discovery of molecular principles and therapeutic targets, to development 
involving clinical trials that prove efficacy and safety, through regulatory approval that 
certifies the utility of the management approach, to application in patients and 
populations – the “DDRU continuum”.3, 9-12 This model broadly categorizes the stages 
translating invention into practice. However, it obscures the integral contributions by 
individual practitioners and domain-specific experts, and the impact of the external 
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environment, which shape the process at every phase, from discovery to application. 
Without considering these individual components, their contributions, and their 
relationship to the over-arching continuum, we risk under-estimating points of 
vulnerability which can constrain or potentiate the innovation that serves as the lifeblood 
of personalized medicine. 
It is useful here to borrow a page from the manufacturing sciences to consider 
the advanced product development continuum in the context of supply chain 
management. In this model, the movement and storage of raw materials, work-in-
process inventories, and finished products from the point of origin to the point of use is 
strategically managed to create net value with a competitive infrastructure, 
synchronizing supply with demand, and measuring performance globally across the 
entire enterprise.13 Indeed, supply chain strategies require a total systems view of the 
links in the chain that work together efficiently to create customer satisfaction at the 
endpoint of product delivery to the consumer. Efficiencies must be maximized at each of 
the component steps to produce added value across the entire continuum to optimize 
the benefit to the end user. This concept focuses on total systems efficiency to produce 
optimum value by generating the best product while minimizing waste and inefficiency. 
In this model, the supply chain is the set of organizations and processes linked by one 
or more upstream and downstream flows of products or information from a source to an 
end user.  
By analogy, the DDRU continuum can be considered a type of product 
development/supply chain, with the raw materials of intellectual innovation in 
combination with specimens, reagents, and biologicals undergoing transformation by 
discovery scientists, clinical trialists, regulatory scientists and clinicians into integrated 
diagnostic and therapeutic paradigms that embody personalized medicine for end users 
including patients, their healthcare providers, and payers. The essential nature of raw 
materials to this supply chain is exemplified by the Commentary by Lu and Flockhart, 
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who propose a national program to collect annotated biospecimens, similar to the 
national model for organ donor identification. These authors underscore the critical 
vulnerability of the DDRU continuum and innovation in individualized medicine in the 
context of limitations in the availability of biospecimens accompanied by full clinical and 
demographic annotation. Indeed, in the absence of this essential national resource, the 
ability to translate novel genomic observations identified in the laboratory into useful 
diagnostic and therapeutic targets that can be applied to disease-specific tailoring of 
patient management will undergo progressively greater levels of constraint. These 
constraints reflect an inability to validate and confirm clinical utility of the many genomic 
associations through standard prospective multicenter blinded clinical trials, which are 
logistically and economically infeasible. Rather, retrospective validation of clinical utility 
employing annotated biospecimens from a national repository represents an adaptive 
solution that creatively aligns resources with needs to maximize value of discoveries to 
end users of personalized medicine while minimizing costs and inefficiencies. 
Moving along the supply chain, laboratory-based investigations are using those 
essential biospecimens in conjunction with emerging technology platforms to create 
molecular diagnostic products that are intrinsic components of the personalized 
medicine paradigm.12, 14 These diagnostics identify pathophysiological biomolecules 
used for disease prediction, risk assessment, prognosis, and diagnosis. Further, these 
diagnostics can identify genetic variations in patients creating susceptibility to adverse 
therapeutic events. In his Commentary, Kesselheim highlights the recent Supreme 
Court decision against the patentability of natural processes.15 For example, developing 
a test identifying genetic variants that render patients unable to metabolize a drug, 
putting them at risk for toxic adverse events, is ineligible for patentability. Similarly, tests 
that define genetic mutations providing prognostic information predicting disease 
outcome also cannot be protected by patents. Here, policy decisions external to the 
scientific process may negatively shape the supply chain of innovation available to 
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expand personalized medicine. Indeed, the absence of patent protection for these, and 
related, discoveries creates an economic vulnerability in the innovation supply chain, 
reflecting the absence of a period of market exclusivity for these discoveries 
characteristically granted through patent protection. This economic vulnerability 
threatens the flow of innovation by constraining investment in the development of 
intellectual property that cannot be patent protected. This absence of market exclusivity 
could strangle the supply of novel diagnostic products that are essential for downstream 
processes translating scientific innovation into the clinical tools supporting the evolution 
of personalized medicine. 
The negative impact of these policy decisions concerning intellectual property 
stands as a striking counterpoint to the innovation in pharmacometabolomics underscored 
by Kaddurah-Daouk and her colleagues.16 This State of the Art review highlights the 
transformative potential of the study of metabolism at the omic level, to reveal novel molecular 
mechanisms underlying inter-individual variability in pathophysiology, drug action, and the 
evolution of adverse responses to therapeutics. In turn, these emerging mechanistic insights will 
form the basis for novel diagnostic tests based on metabolic signatures of patients that can 
specifically target individualized therapeutic approaches, to expand the supply chain of 
innovation feeding the personalized medicine paradigm.17-21 Similarly, Momper and Wagner in 
their Development remind us of the essential utility of therapeutic drug monitoring as a 
cornerstone of classical clinical pharmacology practice which has its origins in the pre-genomic 
era.22 This approach continues to provide unique insights into inter-individual variability in 
therapeutic responses and adverse events to drugs, especially in cohorts that exhibit highly 
dynamic metabolic phenotypes, like the pediatric population. Indeed, co-development of 
companion drug monitoring algorithms that accompany novel therapeutic approaches has the 
potential to dampen the variability in therapeutic and adverse responses to interventions, 
generally, in patient populations, suggesting a position for these approaches in strategies of 
supply chain management associated with the development of emerging targeted therapies.22 In 
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that context, it will be important to monitor whether the recent Supreme Court decisions on 
intellectual property15 have a negative impact on the advancement of pharmacometabolomics or 
companion therapeutic drug monitoring approaches as novel diagnostics driving innovation in 
personalized medicine. 
Toward the other end of the supply chain, there are emerging challenges in confirming 
the utility of novel diagnostic and therapeutic approaches at the center of personalized 
medicine. Selker and his colleagues highlight in their State of the Art the potential for standard 
clinical development approaches to over-estimate the utility of emerging paradigms in 
personalized medicine in general clinical practice. As these emerging approaches embrace 
higher orders of molecular specificity and patient individualization, there is a requirement for 
standard phase III efficacy trial designs to use highly homogenous populations of patients 
carrying the molecular target of interest to reveal clinical efficacy. In that context, efficacy 
revealed in these trials may be sufficient to achieve regulatory approval, but may not translate 
into true effectiveness in actual clinical practice, where patients are highly heterogeneous with 
respect to genotypes and phenotypes, and environments and demographics cannot be closely 
defined or controlled. In order to improve the flow of novel technological advancements along 
the supply chain from the point of innovation in the laboratory to end users like patients, 
healthcare providers and payers, Selker and his colleagues suggest evolving the standard 
phase III paradigm into efficacy-effectiveness trials.22 In this model, therapeutic interventions 
successfully completing standard phase III efficacy trials in narrowly defined patient populations 
would immediately transition into effectiveness trials to estimate the true utility of these 
approaches in heterogeneous populations that constitute actual medical practice. 
Finally, at the very end of the supply chain, the deluge of omic information, its 
relationship to clinical practice, and its utility in maximizing improvements in patient 
outcomes while minimizing healthcare costs continues to remain a conundrum to 
patients, providers and payers. What are the criteria that support the utility of specific 
omic platforms in patient management paradigms? How should patients and providers 
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assess those criteria for their utility, and how should payers assess their ratio of cost to 
benefit? It is readily apparent that without solving this conundrum, the supply chain 
transforming invention and innovation into end user value will prematurely terminate. In 
their State of the Art review, Dotson and colleagues offer one23 of a number24-34 of 
algorithms to assess the evidence base supporting implementation of genomic 
information into clinical practice and patient management. 
Personalized medicine is having a transformative impact on disease risk 
assessment, prediction, prevention, prognosis and cure.9, 11 The present discussion 
highlights the operational flow of technology along a supply chain of innovation, from 
laboratory to end users, which requires management at each individual step to 
maximize healthcare and economic benefits. Our challenge is to establish the policies 
and processes that become an engine driving innovation through this cascade, rather 
than a weight dragging down the system. 
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